These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11057353)

  • 1. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
    Brodsky M
    Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
    Abelson MB; Welch DL
    Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J; Discepola M; Abelson M
    Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
    Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
    Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB; Turner D
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
    Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
    Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the use of olopatadine in allergic conjunctivitis.
    McGill JI
    Int Ophthalmol; 2004 May; 25(3):171-9. PubMed ID: 15847317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.
    Corum I; Yeniad B; Bilgin LK; Ilhan R
    J Ocul Pharmacol Ther; 2005 Oct; 21(5):400-5. PubMed ID: 16245967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.